Treatment of hirsutism with combined pill containing drospirenone

References

• Sperling L C, Heimer W L. Androgen biology as a basis for the diagnosis and treatment of androgenic disorders in women II. J Am Acad Dermatol 1993; 28: 901–916
   Google Scholar
• Rittmaster R S. Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 1995; 98(Suppl 1A)175–215
   Google Scholar
• Tackling polycystic ovary syndrome. Drug Ther Bull 2001; 39: 1–5
   Google Scholar
• Murphy A A, Crop C S, Smith B S, Burkman R T, Zacar H A. Effect of low dose oral contraceptive on gonadotrophins, androgens and sex hormone binding globulin in non hirsute women. Fertil Steril 1990; 53: 35–39
   PubMed Web of Science ®Google Scholar
• Boschitsch E, Skarabis H, Wuttke W, Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effects on well being. Eur J Contracept Reprod Health Care 2000; 5(Suppl)34–40
   Google Scholar
• Blode H, Wuttke W, Loock W, Röll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000; 5: 256–264
   PubMedGoogle Scholar
• Parsey K S, Pong A. An open-label multicentre study to evaluate Yasmin, a low dose combination oral contraceptivecontaining drospirenone, a new progestogen. Contraception 2000; 61: 105–111
   PubMed Web of Science ®Google Scholar
• Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99–110
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Shultz W. Hormonal contraception. 2nd ed. Berlin, Schering 1996
   Google Scholar
• Ferriman D, Gallwey J D. Clinical measurement of body hair growth in women. J Clin Endocrinol 1961; 21: 1440–1447
   PubMed Web of Science ®Google Scholar
• Darney P D. The androgenicity of progestins. Am J Med 1995; 98(Suppl 1A)104s–110s
   Google Scholar
• Cerel-Suhl S L, Yeager B F. Update on oral contraceptive pills. Am J Obstet Gynecol 1999; 179: 577–582
   Google Scholar
• Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–251
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric 2007; 10(Suppl 1)11–18
   Google Scholar
• Fruzzetti F, Lello S, Lazzarini V, Fratta S, Orr[ugrave] M, Sorge R, Minerba L, Ricci C, Genazzani A R, Melis G B, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 2007; 75: 199–203
   PubMed Web of Science ®Google Scholar
• van Vloten W A, van Haselen C W, van Zuuren E J, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69(Suppl 4)2–15
   Google Scholar
• Spellacy W N. Carbohydrate metabolism during treatment with estrogen, progesterone low dose contraceptives. Am J Obstet Gynecol 1982; 142: 732–734
   PubMed Web of Science ®Google Scholar
• Thorneycroft I H. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 2002; 47(Suppl 11)975–980
   Google Scholar
• Chapman M G, Jeffcoate S L, Dewhurst C J. Effect of cyproterone acetate, ethinyl oestradiol treatment on adrenal function in hirsute women. Clin Endocrinol (Oxf) 1982; 17: 577–582
   Google Scholar
• Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89: 2817–2823
   PubMed Web of Science ®Google Scholar
• Batukan C, Muderris I I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85: 436–440
   PubMed Web of Science ®Google Scholar
• Nader S, Ria-Gabriel M G, Saad M F. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997; 85: 3161–3168
   Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H. Tapanainen JS. Metformin versus ethinyl estradiol–cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003; 88: 148–156
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart J M, Dombrovicz N, Welter A, Heithecker R. Effects of new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821
   PubMed Web of Science ®Google Scholar
• van Grootheest K, Vrieling T. Drug points: thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326: 257
   PubMedGoogle Scholar